Graph Blockchain Declares Launching of BluStem, Ecommerce Wellness Platform
Graph Blockchain Inc. announced the expansion and future roll-out of its proprietary Wellness Marketplace platform, BluStem Ltd., a wholly-owned subsidiary of Graph Blockchain Inc. The roll-out of the site will start around the week of June 1st, 2020. The Company will be building an eCommerce ecosystem for B2C and B2B audiences in aid of scaling both its own and its partner brands.
The Company will begin highlighting COVID-19 related products like Personal Protective Equipment (PPE) and a COVID-19 Test Service once it has settled the sourcing of products. The Company also intends to expand to CBD, Fungi/Psychedelics, and other wellness brands for the second phase. The Company anticipates significant income growth by the BluStem eCommerce platform from the sale of products, marketing, licensing, and product fulfillment fees, including the Company’s brand “BluStem” that will leverage white-labeling supply chain business agreements. The Company will not be setting up its capital for the PPE products due to its broker relationship.
As a consequence of current worldwide events linking to the COVID-19 pandemic and the ensuing slowdown of action in all sectors of business, the Company is using the opportunity to support Canadians and Canadian Companies to return to secure working environments by the BluStem platform’s online eCommerce Marketplace(s) that will concentrate on Personal Protective Equipment (PPE) and COVID-19 test services with plans to extend to other wellness products like CBD, Psychedelics and other wellness brands.
Graph President & CEO, Christian Scovenna said in a statement that, “These are exciting times for the Company and its shareholders, as we are poised to move in a direction using our current core technology. With today’s announcement of our BluStem eCommerce marketplace, we are pursuing the creation of a revenue model that facilitates both scale and organic growth.”
The Company declares that it has granted 15,828,458 incentive stock options to directors, officers, and consultants. The incentive stock options have an exercise price of $0.05 per share, are efficient for three years from the date of grant and are subject to regulatory approval.
The Company’s Stock Option Plan provides for the issuance of up to 10% of issued and outstanding share capital in the sort of incentive stock options. As a consequence of this grant, the Company has 14,250,000 stock options published, designating 9.2% of the issued and outstanding share capital. The stock option plan directed to Shareholder approval at the upcoming Annual General Meeting (AGM).